Advanced Technology Ventures
VC Fund
Menlo Park, United States
Advanced Technology Ventures (ATV) is a bi-coastal venture capital firm that focuses on communications, infrastructure, software and services, consumer technology, biopharmaceuticals, medical devices and cleantech.
- Total investments:
- 159
- Last investment:
- Lead investor:
- 26%
- Fund size:
- $303M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Advanced Technology Ventures invests in
Health CareBiotechnologySoftwareMedicalMedical Device
Stages Advanced Technology Ventures invests in
Series BSeries CSeries DSeries AFunding Round
Countries Advanced Technology Ventures invests in
United StatesIndiaCanadaFrance
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Steve Baloff
|
|||
Bill Wiberg
|
|||
Bob Hower
|
|||
Jean George
|
|||
Mike Carusi
|
Investment Focus
Industry
- Health Care 23 (14%)
- Biotechnology 21 (13%)
- Software 20 (13%)
- Medical 15 (9%)
- Medical Device 15 (9%)
Stage
- Series B 37 (23%)
- Series C 35 (22%)
- Series D 21 (13%)
- Series A 18 (11%)
- Funding Round 14 (9%)
Country
- United States 80 (50%)
- India 1 (1%)
- Canada 1 (1%)
- France 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Steve Baloff
Managing Director
|
Managing Director | Total investments: 17 | Find email | |
|
Bill Wiberg
General Partner
|
General Partner | Total investments: 22 | Find email | |
|
Bob Hower
General Partner
|
General Partner | Total investments: 31 | Find email | |
|
Jean George
General Partner
|
General Partner | Total investments: 14 | Find email | |
|
Mike Carusi
General Partner
|
General Partner | Total investments: 17 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Nuvaira
|
Nuvaira is a new alternative COPD treatment option that specializes in developing devices for treating lung diseases. Nuvaira is currently working on a novel catheter-based system that has the potential to improve lung function, exercise capacity, and quality of life for patients with chronic obstructive pulmonary disease.It was founded in 2008and headquartered in Minneapolis, Minnesota. | $79M / Series E / Feb 11, 2019 | |
Actifio
|
Actifio delivers Enterprise Data-as-a-Service to hundreds of global enterprise customers and service provider partners in more than 30 countries.Actifio helps hundreds of global enterprise customers and service provider partners in more than 30 countries around the world virtualize their data, just as they virtualized their servers and networks.Their Virtual Data Pipeline™ technology decouples data from infrastructure, enabling dramatic improvements in business resiliency, agility, and access to the cloud.Actifio replaces siloed data management applications with a radically simple, application-centric, SLA-driven approach that lets customers capture data from production applications, manage it more economically, and use it when and where they need. The result is enterprise data available for any use, anytime, anywhere, for less. | $100M / Series F / Aug 07, 2018 | |
EndoGastric Solutions
|
EndoGastric Solutions, Inc. (www.endogastricsolutions.com), is a medical device company developing and commercializing innovative, evidence-based, incisionless surgical technology for the treatment of GERD. EGS has combined the most advanced concepts in gastroenterology and surgery to develop the Transoral Incisionless Fundoplication (TIF®) 2.0procedure—a minimally invasive solution that addresses a significant unmet clinical need.EndoGastric Solutions, Inc. was founded in 2003 and is headquartered in Redmond, Washington. | $40.6M / Series I / Jun 19, 2018 | |
Gynesonics
|
Gynesonics is a women’s healthcare company focused on the development of advanced incision-free solutions for the treatment of uterine conditions. Gynesonics serves customers worldwide. It was founded in 2005 and is headquartered in Redwood City, California. | $75M / Private Equity / Jan 03, 2018 | |
Oasys Water
|
Oasys (Osmotic Application Systems) is a privately held Boston, MA based company developing a suite of proprietary energy and resource recovery products to address the growing, global water crisis. Engineered Osmosisâ„¢ (EOâ„¢) is a platform for reducing cost in the production of clean water, power and energy through more efficient and sustainableutilization of resources. | $4M / Series B / Mar 03, 2017 | |
Second Genome
|
Second Genome’s mission is to transform lives with medicines developed through innovative microbiome science. Second Genome has built a novel platform for microbiome drug discovery. Second Genome has completed more than 400 microbiome studies, analyzing more than 75,000 samples, for internal R&D, as well as for external partners acrossgovernment, academia, pharmaceutical, nutrition and industrial companies. The team leverages its microbiome analysis platform with its partners’ specific expertise to generate insightful findings that can accelerate research programs by elucidating the role of the microbiome in human health conditions, agriculture, animal health and other industries. The company has established a pipeline of therapeutic products for the treatment of inflammation and metabolic diseases. | $51M / Series B / Apr 13, 2016 | |
Cedexis
|
Founded in 2009 by Marty Kagan and Julien Coulon, two veterans of web hosting and content delivery market, Cedexis optimizes web performance across data centers, delivery networks and clouds for companies that want to reach new global markets. With Cedexis, companies can comparatively assess worldwide cloud performance and availability forinformed vendor selection and making cost-and-performance tradeoffs. Cedexis also provides adaptive automation for dynamically optimizing traffic across clouds, data centers and delivery networks to dynamically match the best-performing clouds with local demand. Since revenue conversions and brand experience are directly tied to online performance, media, retail and consumer branded companies rely on Cedexis to ensure 100% availability, fast page loads, downloads and transactions to drive traffic and revenue at lower cost and risk.Cedexis is headquartered in Portland (OR) and Paris (EMEA) with offices in San Francisco (CA), London (UK) and sales representatives in Germany, Japan, Israel and Brazil. | $22M / Series B / Jan 26, 2016 | |
|
EndoGastric Solutions
|
EndoGastric Solutions, Inc. (www.endogastricsolutions.com), is a medical device company developing and commercializing innovative, evidence-based, incisionless surgical technology for the treatment of GERD. EGS has combined the most advanced concepts in gastroenterology and surgery to develop the Transoral Incisionless Fundoplication (TIF®) 2.0procedure—a minimally invasive solution that addresses a significant unmet clinical need.EndoGastric Solutions, Inc. was founded in 2003 and is headquartered in Redmond, Washington. | $50M / Dec 01, 2015 | |
|
Gynesonics
|
Gynesonics is a women’s healthcare company focused on the development of advanced incision-free solutions for the treatment of uterine conditions. Gynesonics serves customers worldwide. It was founded in 2005 and is headquartered in Redwood City, California. | $43M / Jul 22, 2015 | |
Thrasos
|
Thrasos is a bio-therapeutics company focused on the discovery and development of targeted therapies for the prevention and treatment of severe organ failure, with a principle focus on kidney disease. The Company's lead therapeutic program, THR-184, is focused on the prevention and treatment of acute kidney injury (AKI). The Company also has apreclinical development program for treating chronic kidney disease (CKD). | $21M / Series D / Mar 31, 2015 | |
| See all 159 investments → | |||
Co-Investors
Morgenthaler Ventures
14 deals together
MPM Capital
11 deals together
Abingworth
10 deals together
Bessemer Venture Partners
10 deals together
Foundation Medical Partners
9 deals together
Delphi Ventures
8 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
SaaS Investors
99,274 investors
Software Investors
50,021 investors
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Medical Device Investors
11,047 investors
SaaS VC Funds
61,208 investors
Software VC Funds
31,919 investors
FAQ
What does Advanced Technology Ventures invest in?
Advanced Technology Ventures invests primarily in Health Care, Biotechnology and Software startups, most often at Series B and Series C stage. Most of the 159 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Advanced Technology Ventures?
Public channels for Advanced Technology Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Advanced Technology Ventures?
The team at Advanced Technology Ventures includes Steve Baloff (Managing Director), Bill Wiberg (General Partner) and Bob Hower (General Partner), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
